LEADER 00000cam a2200649Ii 4500 
001    ocn978248730 
003    OCoLC 
005    20180804040027.4 
006    m     o  d         
007    cr cnu|||unuuu 
008    170321s2017    nyua    ob    001 0 eng d 
019    979062587 
020    9781536102987|q(electronic book) 
020    1536102989|q(electronic book) 
020    |z9781536102772 
035    (OCoLC)978248730|z(OCoLC)979062587 
040    N$T|beng|erda|epn|cN$T|dN$T|dEBLCP|dOCLCQ|dOCLCF 
049    RIDW 
050  4 RC918.D53 
072  7 HEA|x039000|2bisacsh 
072  7 MED|x014000|2bisacsh 
072  7 MED|x022000|2bisacsh 
072  7 MED|x112000|2bisacsh 
072  7 MED|x045000|2bisacsh 
082 04 616.462|223 
090    RC918.D53 
245 00 Diabetic nephropathy :|bfrom bench to bedside /|cMingxi Li
       and Jianling Tao, editors. 
264  1 New York :|bNova Science Publishers, Inc.,|c2017. 
300    1 online resource :|billustrations. 
336    text|btxt|2rdacontent 
337    computer|bc|2rdamedia 
338    online resource|bcr|2rdacarrier 
340    |gpolychrome|2rdacc 
347    text file|2rdaft 
490 1  Nephrology research and clinical developments 
504    Includes bibliographical references and index. 
505 0  Preface; New Progress in Diabetic Nephropathy and Local 
       Micro Inflammation; Abstract; Introduction; Diabetic 
       Nephropathy and Local Inflammation; Classic Inflammation 
       in DN; Abnormal Gene Regulation and Local Inflammation in 
       Diabetic Nephropathy; Inflammasome and DN Inflammation; 
       Conclusion; References; Current Findings in The Use of 
       Proteomics Technology for the Diagnosis and Management of 
       Diabetic Nephropathy; Abstract; Introduction; Diabetic 
       Nephropathy; Proteomic Analysis of Diabetic Nephropathy; 
       Proteomic Platforms and Methodologies; Two-Dimensional Gel
       Electrophoresis (2-De). 
505 8  Liquid Chromatography Combined to Mass Spectrometry (Lc-
       Ms)Quantitative Proteomics; Sample Selection: Advantages 
       and Disadvantages; Urine; Plasma; Lessons from Animal 
       Models; Proteomics in the Clinical Setting: Biomarker 
       Discovery; Conclusion and a Future Place in Therapy; 
       References; Clinical Aspects of Diagnosis and Treatment of
       DN; Abstract; Introduction; Diagnosis; Clinical 
       Manifestations; Adjunctive labs; Biopsy Indication [3, 
       15]; Treatment; 1. Lifestyle Modification; 2. Control of 
       Glycated Hemoglobin (Goal of HbA1c: <7.0%); 3. Control of 
       Blood Pressure (Goal of BP: <130/80 mmHg). 
505 8  4. Blockage of RAS5. Improvement in Dyslipidemia; 6. Novel
       Therapies; Conclusion; References; Diabetic Retinopathy; 
       Abstract; Introduction; Pathophysiology; Classification; 
       Symptoms and Signs; Screening and Diagnosis; Treatment; 
       NPDR; PDR; References; Neurological Diseases in Diabetic 
       Nephropathy; Abstract; Introduction; Central Nervous 
       System Diseases; Uremic Encephalopathy; Dementia and 
       Cognitive Impairment; Cerebrovascular Disease; Osmotic 
       Myelinolysis; Movement Disorders and Restless Legs 
       Syndrome; Opportunistic Infections; Neoplasms; 
       Intracranial Hypotension; Intracranial Hypertension. 
505 8  Peripheral Nervous System DiseasesUremic Polyneuropathy; 
       Mononeuropathy; Uremic Myopathy; Autonomic Dysfunction; 
       References; Diabetic Nephropathy and Nutrition; Abstract; 
       Introduction; The Relationship between Nutritional Factors
       and Diabetic Nephropathy; Nutritional Recommendation for 
       Patients with Diabetic Nephropathy (DN); Glycemic Control;
       Intake of Protein; Lipid Management; Restriction of Salt 
       Intake; Vitamin D; Dietary Fiber; Dietary Pattern; 
       Nutritional Consideration for End-Stage Renal Disease 
       (ESRD); References; Renal Replacement Therapy in Diabetic 
       Nephropathy; Abstract. 
505 8  IntroductionWhen to Start Dialysis; How to Choose 
       Dialysis; I. Long-Term Prognosis and Survival; II. 
       Dialysis Adequacy; III. Residual Renal Function; IV. 
       Complications; A. Cardiovascular Disease; B. Infection; C.
       Disturbance of Carbohydrate Metabolism and Glycemic 
       Control; Conclusion; References; Clinical Trial Update on 
       the Way to Cure DN; Abstract; Introduction; New 
       Developments in Glycaemic Control and Blood Pressure 
       Control; Glycaemic Control; Blood Pressure Control; New 
       Approaches; Direct Renin Inhibitor; Inhibitors of AGE 
       Formation; Endothelin Antagonists; Bardoxolone Methyl. 
588 0  Vendor-supplied metadata. 
590    eBooks on EBSCOhost|bEBSCO eBook Subscription Academic 
       Collection - North America 
650  0 Diabetic nephropathies.|0https://id.loc.gov/authorities/
       subjects/sh85037470 
650  7 Diabetic nephropathies.|2fast|0https://id.worldcat.org/
       fast/892229 
655  4 Electronic books. 
700 1  Li, Mingxi,|0https://id.loc.gov/authorities/names/
       n2018024063|eeditor. 
700 1  Tao, Jianling,|0https://id.loc.gov/authorities/names/
       n2018024065|eeditor. 
776 08 |iPrint version:|aLi, Mingxi.|tDiabetic Nephropathy: From 
       Bench to Bedside.|dHauppauge : Nova Science Publishers, 
       Inc., ©2017|z9781536102772 
830  0 Nephrology research and clinical developments series.
       |0https://id.loc.gov/authorities/names/n2010181454 
856 40 |uhttps://rider.idm.oclc.org/login?url=http://
       search.ebscohost.com/login.aspx?direct=true&scope=site&
       db=nlebk&AN=1488015|zOnline eBook. Access restricted to 
       current Rider University students, faculty, and staff. 
856 42 |3Instructions for reading/downloading the EBSCO version 
       of this eBook|uhttp://guides.rider.edu/ebooks/ebsco 
901    MARCIVE 20231220 
948    |d20180907|cEBSCO|tEBSCOebooksacademic NEW 8-3-18 2887 
       |lridw 
994    92|bRID